Рекомендации с позиций общественного здравоохранения
Пересмотренное издание
Программа по ВИЧ/СПИДу
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan...demic laid this inequity bare, it also saw the pharmaceutical industry develop and bring new vaccines and treat- ments to market at unprecedented speed. As the world emerges from the worst
of this crisis, pharmaceutical companies are now at an important juncture, where lessons learned from the pandemic can prove pivotal in finding solutions to bridge long-standing gaps in access to medicine in LMICs.
more
Scant data exists on the prevalence of violence against children worldwide. However, available information, including the United Nations Secretary-General’s Study on Violence against Children, shows that violence against children is a global problem. This desktop study aims to glean from published... and grey literature the extent of sexual violence and exploitation against children in Lesotho. The goal of this study is to better understand the government of Lesotho's national response efforts to reduce violence against children.
more
Research Article
PLOS ONE | DOI:10.1371/journal.pone.0169530 February 16, 2017
A survey of prevention, testing and treatment policies and practices
An action research conducted in Bang Shau village Northern Shan State, Myanmar
Antimicrobial Resistance and Infection Control 2014,3 :31
Tuberculosis cases, TB deaths
The aims of this publication is to highlight the lack of diversity in medical literature and education
One Earth Perspective. Cell Press
This status report shows how far we have come—and how much further we must go—if we hope to meet the global commitments to end AIDS in children. It offers a snapshot of global progress and permits an early assessment of the impact of the Global Alliance’s work.